Adam Asch to Protein Kinase Inhibitors
This is a "connection" page, showing publications Adam Asch has written about Protein Kinase Inhibitors.
Connection Strength
0.086
-
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030.
Score: 0.047
-
"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease. Aging Cell. 2020 03; 19(3):e13109.
Score: 0.039